Prague (ots/PRNewswire) - Zentiva Group announces the completion of
its acquisition of a manufacturing site in Ankleshwar, India, from
Sanofi. The finalization of the deal increases the number of
wholly-owned Zentiva production sites worldwide and will enable
Zentiva to serve more people who are in daily need of our high
quality, affordable medicines.
"We are delighted to welcome the Ankleshwar team into our Zentiva
family. We are continuing to deliver strong growth at Zentiva and the
completion of this acquisition is an important milestone for our
company," said Nick Haggar, Chief Executive Officer of Zentiva. "The
strength of our growing manufacturing network and additional capacity
means we can keep pace with the accelerating demand for our medicines
and increase our direct control over our supply chain to help ensure
continuous supply and rapid response to patient needs."
The transaction continues the flow of decisive growth moves made by
Zentiva, building on earlier acquisitions of Creo Pharma in the UK,
Solacium in Romania and the Central and Eastern European operations
of Alvogen completed in April 2020. This latest acquisition in India
runs in parallel to the ongoing multiple multi-million Euro
investments at Zentiva's flagship sites in Prague and Bucharest.
"I am so proud that our Ankleshwar team will be part of an even
stronger Zentiva, integrated into the organization's long-term growth
strategy," added Ashwani Sood, Head of the Ankleshwar site. "We know
demand for high quality and affordable medicines is increasing and we
look forward to contributing to Zentiva's success on this journey."
The manufacturing site will be supported by a brand new Zentiva India
affiliate office in Mumbai.
Zentiva is a producer of high-quality affordable medicines serving
patients in Europe and beyond. With a dedicated team of more than
4,700 people and a network of production sites - including flagship
sites in Prague, Bucharest and Ankleshwar - Zentiva strives to be the
champion of branded and generic medicines in Europe to better support
people's daily healthcare needs.
At Zentiva it is our aspiration that healthcare should be a right and
not a privilege. More than ever, people need better access to high
quality affordable medicines and healthcare. We work in partnership
with physicians, pharmacists, wholesalers, regulators and governments
to provide the everyday solutions that we all depend on.
Learn more about Zentiva on www.zentiva.com.
About Zentiva's Ankleshwar site
Established in 1987, the Ankleshwar manufacturing site has a
chemistry and biotechnology development center, and manufactures both
intermediates and pharmaceutical formulations. A large producer of
tablets, the Ankleshwar site manufactures more than 6 billion tablets
Logo - https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg
Mounira LemouiHead of CommunicationsZENTIVA GROUP, a.s.
U kabelovny 529/16, Dolní M?cholupy, 102 00 Prague 10
Cell: (+420) 727 873 159
Digital press kit: http://www.ots.at/pressemappe/PR132270/aom
Aktien auf dem Radar:Semperit, Frequentis, Marinomed Biotech, Warimpex, Telekom Austria, Palfinger, Amag, Pierer Mobility AG, Strabag, Zumtobel, DO&CO, AMS, AT&S, Cleen Energy, Flughafen Wien, Gurktaler AG Stamm.
Erforscht und entwickelt völlig neuartige Technologieplattformen, die innovative Therapien gegen Atemwegs- und Augenerkrankungen ermöglichen. Aus wissenschaftlichen Ideen werden so neue Patente, Marken und Produkte geschaffen.
>> Besuchen Sie 55 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER